Below are the most recently updated broker updates which include ratings and price targets for Anthera Pharmaceuticals, Inc. (ANTH).

03/11/2016 – Broker: Piper Jaffray Rating: overweight New Target: 10 reiteration

02/19/2016 – Broker: Jefferies Rating: buy New Target: 9 reiteration

09/17/2015 – Broker: Citigroup Rating: buy New Target: 15 newcoverage

09/09/2015 – Broker: SunTrust Rating: buy New Target: 14 newcoverage

05/01/2015 – Broker: Zacks Rating: buy New Target: 5.75 reiteration

02/24/2014 – Broker: Thomson Reuters/Verus Rating: buy upgrade

The average price target from the most recent broker reports is 10.75

The stock decreased -3.21% (-0.10) during the last days session, reaching 3.02 and roughly 707167 shares were bought or sold by traders.

View other investors thoughts on Anthera Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.